# Experimental Medicine Study to Validate Pharmacodynamic Pain Assessments in Healthy Volunteers With an Opioid Analgesic (Remifentanil)

> **NCT02602002** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 20 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Remifentanil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02602002
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02602002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02602002, "Experimental Medicine Study to Validate Pharmacodynamic Pain Assessments in Healthy Volunteers With an Opioid Analgesic (Remifentanil)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02602002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*